RSS-Feed abonnieren
DOI: 10.1055/s-2006-940056
© Georg Thieme Verlag KG Stuttgart · New York
Dyslipidämie bei langjähriger neuroleptischer Behandlung
Dyslipidemia and SchizophreniaPublikationsverlauf
Publikationsdatum:
07. Dezember 2006 (online)
![](https://www.thieme-connect.de/media/psychiat-praxis/200705/lookinside/thumbnails/10.1055-s-2006-940056-1.jpg)
Zusammenfassung
Anliegen Unter Atypikabehandlung können Fettstoffwechselstörungen auftreten. Daher wurden die Serumlipidwerte bei Patienten mit chronischer Schizophrenie untersucht. Methode Serumlipidwerte von 177 konsekutiv stationär aufgenommenen schizophrenen Patienten, für die Daten über eine Behandlung von mehr als 5 Jahren vorlagen, wurden ausgewertet. Ergebnisse Die Serumlipidwerte zeigten keine Geschlechtsunterschiede. Ein erheblicher Teil der Patienten wies erhöhte Triglyzeridwerte (35,6 %) und/oder Cholesterinwerte (43,9 %) auf. Der Anteil der Patienten mit erhöhten Cholesterin- bzw. Triglyzeridwerten steigt mit der Behandlungsdauer. Die Triglyzeridkonzentration korrelierte mit dem Bodymass-Index (p < 0,01). Schlussfolgerungen Die Studie weist auf einen Zusammenhang zwischen der Häufigkeit erhöhter Lipidserumwerte und der Therapiedauer hin.
Abstract
Objective There is some evidence that the treatment with new („atypical”) neuroleptics is associated with a higher frequency of hyperlipidemia. Aim In this study the serum lipid levels of patients with chronic schizophrenia were investigated. Methods The serum lipid levels of 177 consecutively admitted schizophrenic patients treated at least 5 years were evaluated. Results No gender differences of lipid concentrations could be detected. A considerable rate of the patients (35.6 %) showed elevated triglycerides (> 150 mg/dl) or elevated cholesterol levels (> 200 mg/dl; 43.9 %). The rate of patients with elevated cholesterol or triglyceride concentrations is associated with the duration of treatment. The comparison of different groups of neuroleptics yielded at best a trend to higher triglyceride levels in the patients treated with dibenzodiazepines compared to those receiving only classical neuroleptics. The triglyceride concentrations correlated with the body mass index (ρ = 0.25, p < 0.01). Conclusions This study revealed evidence for an association of the rate of patients with elevated lipid levels and duration of neuroleptic treatment in schizophrenia patients.
Schlüsselwörter
Schizophrenie - Neuroleptika - Dyslipidämie - Triglyzeride - Cholesterin
Key words
schizophrenia - neuroleptics - dyslipidemia - triglycerides - cholesterol
Literatur
- 1 Meyer J M, Koro C E. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res. 2004; 70 1-17
- 2 Wetterling T. Hyperlipidämie - Nebenwirkung von „atypischen” Neuroleptika?. Fortschr Neurol Psychiatr. 2003; 71 535-540
- 3 Atmaca M, Kuloglu M, Tezcan E, Gecici O, Ustundag B. Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol. Schizophr Res. 2003; 60 99-100
- 4 Gaulin B D, Markowitz J S, Caley C F, Nesbitt L A, Dufresne R L. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry. 1999; 156 1270-1272
- 5 Koro C E, Fedder D O, L'Italien G J, Weiss S, Magder L S, Kreyenbuhl J, Revicki D, Buchanan R W. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry. 2002; 59 1021-1026
- 6 Wirshing D A, Boyd J A, Meng L R, Ballon J S, Marder S R, Wirshing W C. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002; 63 856-865
- 7 Almeras N, Despres J P, Villeneuve J, Demers M F, Roy M A, Cadrin C, Mottard J P, Bouchard R H. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry. 2004; 65 557-564
- 8 Lambert B L, Chang K Y, Tafesse E, Carson W. Association between antipsychotic treatment and hyperlipidemia among California Medicaid patients with schizophrenia. J Clin Psychopharmacol. 2005; 25 12-18
- 9 Lindenmayer J P, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy J P, Cooper T B, Chakos M, Lieberman J A. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003; 160 290-296
- 10 McQuade R D, Stock E, Marcus R, Jody D, Gharbia N A, Vanveggel S, Archibald D, Carson W H. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry. 2004; 65, Suppl 18 47-56
- 11 Meyer J M. A rectrospective comparison of weight, lipid, and glucose changes between olanzapine- and risperidone-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002; 63 425-433
- 12 Simpson G M, Glick I D, Weiden P J, Romano S J, Siu C O. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004; 161 1837-1847
- 13 Gupta S, Steinmeyer C, Frank B, Madhusoodanan S, Lockwood K, Lentz B, Keller P. Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy. Am J Ther. 2003; 10 348-355
- 14 Wittchen H-U, Glaesmer H, März W, Stalla G, Lehnert H, Zeiher A M, Silber S, Koch U, Böhler S, Pittrow D, Ruf G. for the DETECT-Study Group . Cardiovascular risk factor in primarycare: methods and baseline prevalence rates - the DETECT program. Curr Med Res Opin. 2005; 21 619-629
- 15 Laaser U. Nutzen und Kosten bei Früherkennung und Frühbehandlung der Hypercholesterinämie. Z Kardiol. 1994; 83, Suppl 6 163-167
- 16 Richter W O, Richter V, Rassoul F, Sonnichsen A C, Rotzsch W, Schwandt P. Kardiovaskuläre Risikofaktoren in den alten und neuen Bundesländern. Fortschr Med. 1993; 111 214-218
- 17 Spelsberg A, Weiland K, Stolpe S, Segerling M, Keil U. Bochumer Cholesterin und Blutdruckscreening-Studie 1990. Fortschr Med. 1992; 110 387-392
- 18 Assmann G, Schulte H. The importance of triglycerides: results from the Prospective Cardiovascular Munster (PROCAM) Study. Eur J Epidemiol. 1992; 8, Suppl 1 99-103
- 19 Richter V, Rassoul F, Hentschel B, Kothe K, Krobara M, Unger R, Purschwitz K, Rotzsch W, Thiery J, Muradian K. Age-dependence of lipid parameters in the general population and vegetarians. Z Gerontol Geriatr. 2004; 37 207-213
- 20 Saari K, Koponen H, Laitinen J, Jokelainen J, Lauren L, Isohanni M, Lindeman S. Hyperlipidemia in persons using antipsychotic medication: a general population-based birth cohort study. J Clin Psychiatry. 2004; 65 547-550
- 21 Lund B C, Perry P J, Brooks J M, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry. 2001; 58 1172-1176
- 22 Osser D N, Najarian D M, Dufresne R L. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry. 1999; 60 767-770
- 23 Meyer J M. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol. 2001; 21 369-374
- 24 Henderson D C, Cagliero E, Gray C, Nasrallah R A, Hayden D L, Schoenfeld D A, Goff D C. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry. 2000; 157 975-981
- 25 Henderson D C, Nguyen D D, Copeland P M, Hayden D L, Borba C P, Louie P M, Freudenreich O, Evins A E, Cather C, Goff D C. Clozapine, Diabetes Mellitus, Hyperlipidemia, and Cardiovascular Risks and Mortality: Results of a 10-Year Naturalistic Study. J Clin Psychiatry. 2000; 66 1116-1121
- 26 International Diabetes Federation .The IDF consensus worldwide definition of the metabolic syndrome. 2005 www.idf.org
- 27 Dilling H, Mombour W, Schmidt M H. Internationale Klassifikation psychischer Störungen. ICD-10 Kapitel V (F) Klinisch-diagnostische Leitlinien. 4. Aufl,. Bern; Huber 2000
- 28 Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry. 2000; 177 212-217
- 29 Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Mental disorders and cause-specific mortality. Br J Psychiatry. 2001; 179 498-502
- 30 Palmer B A, Pankratz V S, Bostwick J M. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005; 62 247-253
- 31 Curkendall S M, Mo J, Glasser D B, Rose Stang M, Jones J K. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatry. 2004; 65 715-720
- 32 Enger C, Weatherby L, Reynolds R F, Glasser D B, Walker A M. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis. 2004; 192 19-27
- 33 Casey D E, Haupt D W, Newcomer J W, Henderson D C, Sernyak M J, Davidson M, Lindenmayer J P, Manoukian S V, Banerji M A, Lebovitz H E, Hennekens C H. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004; 65, Suppl 7 4-18
- 34 Wetterling T. Hyperlipidämienebenwirkung bei Behandlung mit einem atypischen Neuroleptikum (Zotepin)?. Psychiat Prax. 2002; 29 438-440
- 35 Baymiller S P, McMahon R P, Buchanan R W. Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. Schizophr Res. 2003; 59 49-57
- 36 Consensus Development . Conference on Antipsychotic Drugs and Obesity and Diabetes. J Clin Psychiatry. 2004; 65 265-272
- 37 Marder S R, Essock S M, Miller A L, Buchanan R W, Casey D E, Davis J M, Kane J M, Lieberman J A, Schooler N R, Covell N, Stroup S, Weissman E M, Wirshing D A, Hall C S, Pogach L, Pi-Sunyer X, Bigger Jr J T, Friedman A, Kleinberg D, Yevich S J, Davis B, Shon S. Physical health monitoring of patients in schizophrenia. Am J Psychiatry. 2004; 161 1334-1349
Prof. Dr. Tilman Wetterling
Klinik für Psychiatrie und Psychotherapie, Vivantes Klinikum Hellersdorf
Myslowitzer Straße 45
12621 Berlin
eMail: tilman.wetterling@vivantes.de